Product Description
Epinastine is a medication used in the treatment and management of allergic conjunctivitis. Epinastine belongs to the class of second-generation antihistamines and is also a mast cell stabilizer. It also shows anti-leukotriene, anti-PAF, and anti-bradykinin activities, which provide additional anti-allergic activities. Antihistamines and mast cell stabilizers have been used to manage various allergic conditions for many years. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557538/)
Mechanisms of Action: H1 Antagonist,H2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Brazil | Chile | Colombia | Czech | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Pakistan | Peru | Poland | Portugal | Russia | Saudi Arabia | Slovakia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Conjunctivitis, Allergic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZKO-EPI-202111 | P3 |
Completed |
Conjunctivitis, Allergic |
2023-11-02 |
56% |
| jRCT2031210639 | P3 |
Completed |
Conjunctivitis, Allergic |
2022-08-25 |
|
| jRCT2051220050 | P3 |
Completed |
Conjunctivitis, Allergic |
2022-08-20 |
|
| jRCT2031220074 | P3 |
Completed |
Conjunctivitis, Allergic |
2022-07-12 |